Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 15/20 | 1.00 |
| ▸ | RIPK1 | Q13546 | 8/20 | 1.00 |
| ▸ | EIF2AK2 | P19525 | 3/20 | 1.00 |
| ▸ | EIF2AK1 | Q9BQI3 | 3/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 2/20 | 1.00 |
| ▸ | MAP3K10 | Q02779 | 2/20 | 1.00 |
| ▸ | MERTK | Q12866 | 2/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 2/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 2/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 2/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29403654 | 1.00 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL30500616 | 1.00 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL868254 | 1.00 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL28589747 | 0.93 | EIF2AK3 (0.87) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL869189 | 0.90 | RIPK1 (0.82) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL869448 | 0.90 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL870488 | 0.90 | RIPK1 (0.81) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL869419 | 0.90 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL28814384 | 0.90 | EIF2AK3 (0.86) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL29433603 | 0.90 | EIF2AK3 (0.81) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616656-B2 | Adventitial painting modality of local drug delivery to abate intimal hyperplasia | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-05-05 | — | — | US | claimed |
| EP-3368037-B1 | NOVEL METHODS OF TREATING HEARING LOSS | UNIV CALIFORNIA (US) | 2026-04-08 | — | — | EP | claimed |
| US-12582613-B2 | Biomimetic, reactive oxygen species-detonable nanoclusters for antirestenotic therapy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-03-24 | — | — | US | claimed |
| US-20260021099-A1 | Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress | UNIV CALIFORNIA (US) | 2026-01-22 | — | — | US | claimed |
| US-12427148-B2 | Cancer treatment targeted to tumor adaptive responses to protein synthesis stress | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-30 | — | — | US | claimed |
| US-12161726-B2 | Biomimetic vesicles and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-12-10 | — | — | US | claimed |
| EP-3593817-B1 | COMPOSITION FOR USE IN THE PREVENTION OR SUPPRESSION OF MYOPIA | TSUBOTA LAB INC (JP) | 2024-11-13 | — | — | EP | claimed |
| US-20240335392-A1 | BIOMIMETIC, REACTIVE OXYGEN SPECIES-DETONABLE NANOCLUSTERS FOR ANTIRESTENOTIC THERAPY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-10-10 | — | — | US | claimed |
| US-20240238198-A1 | AN ADVENTITIAL PAINTING MODALITY OF LOCAL DRUG DELIVERY TO ABATE INTIMAL HYPERPLASIA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-18 | — | — | US | claimed |
| CN-118161473-A | ISRIB application in preparing medicine for preventing and treating ischemic cerebral apoplexy | 苏州大学 | 2024-06-11 | — | — | CN | claimed |
| EP-4051286-A1 | METHODS AND COMPOSITIONS FOR TREATING UVEAL MELANOMA | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-09-07 | — | — | EP | claimed |
| CN-114870020-A | Application of PERK in preventing or treating female reproductive dysfunction or ovarian lesion | 中国人民解放军军事科学院军事医学研究院 | 2022-08-09 | — | — | CN | claimed |
| WO-2022125553-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2022-06-16 | — | — | WO | claimed |
| US-20220152035-A1 | Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-19 | — | — | US | claimed |
| US-20220105061-A1 | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY INSUFFICIENCY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-07 | — | — | US | claimed |
| CN-112807434-B | Application of PERK inhibitor in preparation of synergist of liver cancer drug | 中山大学 | 2022-04-05 | — | — | CN | claimed |
| CN-112402424-B | Small molecule medicine and application thereof in treating intermittent hypoxia | 杭州医学院 | 2022-03-29 | — | — | CN | claimed |
| CN-114177300-A | Composition for inhibiting pancreatic cancer cell proliferation by taking PERK and CTR1 as combined target and application thereof | 吉林省壹诚生物科技有限公司 | 2022-03-15 | — | — | CN | claimed |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | claimed |
| US-11253522-B2 | Cancer treatment targeted to tumor adaptive responses to protein synthesis stress | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021099-A1 | Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress | MYC, MYCBP, EIF4EBP1 | EIF2AK3 14/4885RIPK1 1021/4885EIF2AK2 124/4885 |
| US-12582613-B2 | Biomimetic, reactive oxygen species-detonable nanoclusters for antirestenotic therapy | EXOSC10, CD47, CD63 | EIF2AK3 2619/4885RIPK1 3852/4885EIF2AK2 1428/4885 |
| US-12616656-B2 | Adventitial painting modality of local drug delivery to abate intimal hyperplasia | ADRA1B, ADRB1, ADRB3 | EIF2AK3 3430/4885RIPK1 3013/4885EIF2AK2 2265/4885 |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | INSR, IRS1, INSRR | EIF2AK3 2073/4885RIPK1 160/4885EIF2AK2 1560/4885 |
| US-20240238198-A1 | AN ADVENTITIAL PAINTING MODALITY OF LOCAL DRUG DELIVERY TO ABATE INTIMAL HYPERPLASIA | SHMT1, PNISR, CD44 | EIF2AK3 3684/4885RIPK1 3514/4885EIF2AK2 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.